Cancer Clonal Theory, Immune Escape, and Their Evolving Roles in Cancer Multi-Agent Therapeutics.

Autor: Messerschmidt JL; Main Line Health System, Lankenau Medical Center, 100 W. Lancaster Avenue, Wynnewood, PA, 19096, USA. jlmesser@bu.edu.; Department of Biology, Dr. Thomas Gilmore Laboratory, Boston University, Boston, MA, 02215, USA. jlmesser@bu.edu., Bhattacharya P; Main Line Health System, Lankenau Medical Center, 100 W. Lancaster Avenue, Wynnewood, PA, 19096, USA., Messerschmidt GL; Main Line Health System, Lankenau Medical Center, 100 W. Lancaster Avenue, Wynnewood, PA, 19096, USA.; Precision Oncology, 200 Route 31 North, Suite 102, Flemington, NJ, 08822, USA.
Jazyk: angličtina
Zdroj: Current oncology reports [Curr Oncol Rep] 2017 Aug 12; Vol. 19 (10), pp. 66. Date of Electronic Publication: 2017 Aug 12.
DOI: 10.1007/s11912-017-0625-2
Abstrakt: Purpose of Review: The knowledge base of malignant cell growth and resulting targets is rapidly increasing every day. Clonal theory is essential to understand the changes required for a cell to become malignant. These changes are then clues to therapeutic intervention strategies. Immune system optimization is a critical piece to find, recognize, and eliminate all cancer cells from the host. Only by administering (1) multiple therapies that counteract the cancer cell's mutational and externally induced survival traits and (2) by augmenting the immune system to combat immune suppression processes and by enhancing specific tumor trait recognition can cancer begin to be treated with a truly targeted focus.
Recent Findings: Since the sequencing of the human genome during the 1990s, steady progress in understanding genetic alterations and gene product functions are being unraveled. In cancer, this is proceeding very fast and demonstrates that genetic mutations occur very rapidly to allow for selection of survival traits within various cancer clones. Hundreds of mutations have been identified in single individual cancers, but spread across many clones in the patient's body. Precision oncology will require accurate measurement of these cancer survival-benefiting mutations to develop strategies for effective therapy. Inhibiting these cellular mechanisms is a first step, but these malignant cells need to be eliminated by the host's mechanisms, which we are learning to direct more specifically. Cancer is one of the most complicated cellular aberrations humans have encountered. Rapidly developing significant survival traits require prompt, repeated, and total body measurements of these attributes to effectively develop multi-agent treatment of the individual's malignancy. Focused drug development to inhibit these beneficial mutations is critical to slowing cancer cell growth and, perhaps, triggering apoptosis. In many cases, activation and targeting of the immune system to kill the remaining malignant cells is essential to a cure.
Databáze: MEDLINE
Externí odkaz: